Forbes: "Drug Companies Pin Hopes On TrialReach To Enroll Patients In Clinical Trials Faster"

Major pharmaceutical companies Pfizer, Eli Lilly and Novartis needed a way to get more patients to clinical trials, faster. Forbes covered how TrialReach is bridging that gap:

"It found just the right place. Novartis, Pfizer and Eli Lilly are publicly turning over today their technology at a conference in Boston to a London-based start-up called TrialReach. No matter that its founder, Argentinian-born Pablo Graiver was a foreigner to pharma. 'We wanted to make sure we have a partner willing to maintain openness around data to make it broadly accessible to patients and app developers,' says Craig Lipset, head of clinical innovation at Pfizer."

Read more at Forbes.\